dm+d

Unassigned

New Medicines

Paradase Treatment of parainfluenza virus in immunocompromised patients

Information

Paradase
New molecular entity
Ansun Biopharma
Ansun Biopharma

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Host directed antiviral (first in class). Cleaves sialic acid receptors in the human respiratory tract, which are linked by most of the major respiratory viruses during infection
Parainfluenza viruses (PIV) cause a spectrum of respiratory illnesses, from URIs, 30–50% of which are complicated by otitis media, to LRIs, about 0.3% of which require hospitalisation. About 55,000 to 200,000 patients in hospital in the US are diagnosed with PIV annually. They are often in immunocompromised patients including those undergoing chemotherapy, solid organ transplants and hematopoietic stem cell transplants. [1,2]
Treatment of parainfluenza virus in immunocompromised patients
Inhalation